{"id":13350,"date":"2024-11-18T16:23:27","date_gmt":"2024-11-18T08:23:27","guid":{"rendered":"https:\/\/flcube.com\/?p=13350"},"modified":"2024-11-18T16:23:28","modified_gmt":"2024-11-18T08:23:28","slug":"nk-celltech-partners-with-3sbio-to-advance-nk-cell-therapy-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13350","title":{"rendered":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology"},"content":{"rendered":"\n

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530<\/a>), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization of NK cell therapies.<\/p>\n\n\n\n

NK CellTech’s ABCDE-NK Platform<\/strong>
NK CellTech is known for its innovative off-the-shelf ABCDE-NK industrial production platform, which specializes in the expansion and cryopreservation of allogeneic peripheral blood NK cells. This platform enables the multifunctional, intelligent, and controllable gene editing of NK cells, a critical aspect in the development of effective immunotherapies.<\/p>\n\n\n\n

Collaboration Goals and Scope<\/strong>
The partnership will integrate the respective advantageous technologies and resources of NK CellTech and 3SBio, with the goal of promoting the research and development, clinical study, regulatory filing, and commercialization of licensed technologies and relevant products in the field of NK cell therapy. The collaboration’s scope includes the integration of expertise in NK cell expansion, gene editing, and the development of therapies for various diseases.<\/p>\n\n\n\n

Financial Details and Future Outlook<\/strong>
While no financial details of the partnership have been disclosed, the alliance signals a significant commitment by both companies to push the boundaries of NK cell therapy. The partnership is expected to lead to advancements in the field, potentially offering new treatment options for patients and strengthening the position of both companies in the global biotechnology market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership…<\/p>\n","protected":false},"author":1,"featured_media":13352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,77,1061,757],"class_list":["post-13350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-3sbio","tag-cell-therapy","tag-hkg-1530","tag-nk-celltech"],"yoast_head":"\nNK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization of NK cell therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13350\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13350\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-18T08:23:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-18T08:23:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1125\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology\",\"datePublished\":\"2024-11-18T08:23:27+00:00\",\"dateModified\":\"2024-11-18T08:23:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/883c9e982d23aaa355dc1f9820d36195.jpg\",\"keywords\":[\"3SBio\",\"Cell-therapy\",\"HKG: 1530\",\"NK CellTech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13350#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13350\",\"name\":\"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/883c9e982d23aaa355dc1f9820d36195.jpg\",\"datePublished\":\"2024-11-18T08:23:27+00:00\",\"dateModified\":\"2024-11-18T08:23:28+00:00\",\"description\":\"China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization of NK cell therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13350\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/883c9e982d23aaa355dc1f9820d36195.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/883c9e982d23aaa355dc1f9820d36195.jpg\",\"width\":1125,\"height\":750,\"caption\":\"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13350#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology - Insight, China's Pharmaceutical Industry","description":"China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization of NK cell therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13350","og_locale":"en_US","og_type":"article","og_title":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13350","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-18T08:23:27+00:00","article_modified_time":"2024-11-18T08:23:28+00:00","og_image":[{"width":1125,"height":750,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13350#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13350"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology","datePublished":"2024-11-18T08:23:27+00:00","dateModified":"2024-11-18T08:23:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13350"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=13350#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","keywords":["3SBio","Cell-therapy","HKG: 1530","NK CellTech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13350#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13350","url":"https:\/\/flcube.com\/?p=13350","name":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=13350#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=13350#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","datePublished":"2024-11-18T08:23:27+00:00","dateModified":"2024-11-18T08:23:28+00:00","description":"China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership with 3SBio Inc. (HKG: 1530), a compatriot firm, to focus on advancing NK cell therapy technology. This collaboration aims to leverage the complementary technologies and resources of both companies, accelerating the research, development, and commercialization of NK cell therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13350#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13350"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=13350#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","width":1125,"height":750,"caption":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13350#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/883c9e982d23aaa355dc1f9820d36195.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13350"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13350\/revisions"}],"predecessor-version":[{"id":13353,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13350\/revisions\/13353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/13352"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}